Company intelligence / Profile preview

Lillia

Ownership: Private
Development stage: Commercial

Overview

Lillia has launched a clinically proven AI-powered platform that combines artificial intelligence with expert human coaches—including psychologists, nutritionists, and doctors—to deliver personalized care journeys for individuals with diabetes and related chronic conditions. The approach focuses on developing sustainable micro-habits backed by clinical outcomes. The company has also received a $1.7 million grant from the Qatar Research, Development and Innovation Council to develop the first digital twin in the GCC region focused on chronic conditions.

Therapeutic areas: OtherEndocrinology
Modalities: Non-pharmacological therapyDigital health platformAI-powered behavioral intervention
Industry: Digital Health Medical Devices

Partnerships

Qatar Research, Development and Innovation Council (QRDI Council) – grant funding partnership for technology development

Beyond the preview

Go deeper on Lillia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lillia.

Explore the full profile